false
Catalog
2024 World Conference on Lung Cancer (WCLC) - ePos ...
EP.11A.12 Real-World Treatment Patterns and Clinic ...
EP.11A.12 Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer
Back to course
Pdf Summary
The presentation by Vamsidhar Velcheti at the 2024 World Conference on Lung Cancer focuses on real-world treatment patterns and clinical outcomes after chemotherapy and anti–PD-(L)1 therapy in patients with advanced non-small cell lung cancer (NSCLC). The study utilized a deidentified electronic health record database from Flatiron Health, noting that most data came from community-based practices in the US, which might not reflect the broader patient population's experiences.<br /><br />Key findings include insights into treatment patterns and outcomes in patients who have previously been treated with platinum-based chemotherapy (CT) and anti–PD-(L)1 agents. The study divided patients into three cohorts based on their treatment sequences, analyzing their time to treatment discontinuation (TTD), progression-free survival (PFS), and overall survival (OS). <br /><br />Results highlighted a significant unmet need in this patient population, with median TTD, PFS, and OS being relatively short. Furthermore, outcomes varied depending on the treatment regimens followed. For instance, patients receiving CT combined with immuno-oncology (IO) treatments or IO monotherapy had better outcomes compared to those receiving CT monotherapy. Specifically, Pembrolizumab, as an index treatment, was associated with notably longer OS.<br /><br />Subgroup analyses, though exploratory, suggested variability in outcomes based on treatment and patient characteristics like PD-L1 expression and cancer histology, with longer survival seen in those with 1%-49% PD-L1 expression and non-squamous histology. However, limitations due to the nature of the data, such as potential misclassification and transcription errors, suggest that the findings should be interpreted with caution.<br /><br />The study concludes by emphasizing the need for new treatment approaches, particularly IO combinations, to improve outcomes in this challenging patient group. The research also points to the potential benefits of further exploring novel treatment modalities to extend survival in advanced or metastatic NSCLC.
Asset Subtitle
Vamsidhar Velcheti
Meta Tag
Speaker
Vamsidhar Velcheti
Topic
Metastatic Non-small Cell Lung Cancer – Immunotherapy
Keywords
Vamsidhar Velcheti
World Conference on Lung Cancer
non-small cell lung cancer
NSCLC
chemotherapy
anti-PD-(L)1 therapy
Flatiron Health
treatment patterns
clinical outcomes
immuno-oncology
×
Please select your language
1
English